A new type of gene therapy developed by the U. Oklahoma Health Science Center researchers is giving hope to patients plagued by inherited eye diseases.
Led by researcher Muna Naash, the non-viral gene therapy has shown success in treating the debilitating eye disease retinitis pigmentosa, which blinds an estimated 100,000 Americans, according to a press release.
“This strategy of non-viral gene therapy that we are using is very efficient,” Naash said at a press conference June 9. “There are so many ways we could use this technology.”
Utilizing nanoparticle technology, scientists created a microscopic capsule capable of carrying genetic therapies to their destination inside cells of the retina within 15 minutes, according to the release.
This technique could eventually be used to treat diabetes and certain types of cancers. It also is been used effectively to treat cystic fibrosis and some brain diseases in the laboratory, but hasn’t yet moved to patients, Naash said.
“I am thrilled about it. That’s why we have been working so hard to get this as quickly as possible through the necessary experiments, so we can publish our findings and take it out to the patients,” Naash said. “We want to give Oklahomans and others suffering from these diseases renewed independence and quality of life.”
Tracie Harris, an Oklahoman suffering from retinitis pigmentosa, first discovered her ailment during an eye exam when she was 12 years old.
“We had an idea I had it because my mother had it,” she said.
With no treatment options, Harris could see her vision deteriorating as she got older.
“When I go to a movie theatre, I can see the lights but I can’t see the stairs. I have to have someone help me,” she said. “One thing I miss is seeing lightning bugs and stars. But you learn to take the bumps and the bruises.”
There are many different genes involved in retinitis pigmentosa, and it can be a mild or very aggressive form, said Robert E. Leonard, an ophthalmologist at the Dean McGee Eye Institute.
“The disease typically manifests itself in early adulthood,” Leonard said. “Symptoms such as night blindness and loss of peripheral vision is noticed.”
Naash said she is hopes this treatment process will be taken to patients in the near future. She said the research has been an outcome of many years of hard work.
Leonard said the development is a breakthrough.
“This disease currently is managed with no specific treatment, other than vitamin treatment, which is controversial,” Leonard said.
Harris said she looks forward to the days when she can recover some of the vision she has been missing.
“To know that something like this is happening, it’s a great thing,” Harris said.
For more information on retinitis pigmentosa, visit www.nlm.nih.gov.